CDXC vs. FOMX, CGC, MNMD, BTMD, ACB, MDWD, FTLF, NAII, BGXX, and MTEX
Should you be buying ChromaDex stock or one of its competitors? The main competitors of ChromaDex include Menlo Therapeutics (FOMX), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), MediWound (MDWD), FitLife Brands (FTLF), Natural Alternatives International (NAII), Bright Green (BGXX), and Mannatech (MTEX). These companies are all part of the "medical" sector.
ChromaDex (NASDAQ:CDXC) and Menlo Therapeutics (NASDAQ:FOMX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
15.4% of ChromaDex shares are owned by institutional investors. Comparatively, 46.5% of Menlo Therapeutics shares are owned by institutional investors. 9.6% of ChromaDex shares are owned by company insiders. Comparatively, 3.0% of Menlo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ChromaDex currently has a consensus target price of $6.00, suggesting a potential upside of 117.39%. Given ChromaDex's higher probable upside, analysts plainly believe ChromaDex is more favorable than Menlo Therapeutics.
Menlo Therapeutics has a net margin of 0.00% compared to ChromaDex's net margin of -4.24%. ChromaDex's return on equity of -12.61% beat Menlo Therapeutics' return on equity.
In the previous week, ChromaDex had 3 more articles in the media than Menlo Therapeutics. MarketBeat recorded 3 mentions for ChromaDex and 0 mentions for Menlo Therapeutics. ChromaDex's average media sentiment score of 1.09 beat Menlo Therapeutics' score of 0.00 indicating that ChromaDex is being referred to more favorably in the media.
ChromaDex has higher revenue and earnings than Menlo Therapeutics. ChromaDex is trading at a lower price-to-earnings ratio than Menlo Therapeutics, indicating that it is currently the more affordable of the two stocks.
ChromaDex received 272 more outperform votes than Menlo Therapeutics when rated by MarketBeat users. However, 65.58% of users gave Menlo Therapeutics an outperform vote while only 63.99% of users gave ChromaDex an outperform vote.
ChromaDex has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Menlo Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.
Summary
ChromaDex beats Menlo Therapeutics on 12 of the 17 factors compared between the two stocks.
Get ChromaDex News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ChromaDex Competitors List
Related Companies and Tools
